DAIICHI SANKYO, INC.
- Country
- 🇯🇵Japan
- Ownership
- Subsidiary
- Established
- 2010-01-01
- Employees
- 10K
- Market Cap
- $79B
- Website
- http://daiichisankyo.us
U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer
- Conditions
- Non-Small Cell Lung Cancer (NSCLC)
- Interventions
- Drug: HER3-DXd (FL-DP)Drug: HER3-DXd (CTM-1 Lyo-DP)Drug: HER3-DXd (CTM-3 Lyo-DP)
- First Posted Date
- 2017-08-24
- Last Posted Date
- 2025-03-27
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 309
- Registration Number
- NCT03260491
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸University of California San Diego, La Jolla, California, United States
🇺🇸Pacific Shores Medical Group, Long Beach, California, United States
DS-1205c With Osimertinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
- Conditions
- Non-small Cell Lung Cancer (NSCLC)
- Interventions
- First Posted Date
- 2017-08-21
- Last Posted Date
- 2022-01-19
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 13
- Registration Number
- NCT03255083
- Locations
- 🇨🇳
Taipei Medical University, Shuang Ho Hospital, New Taipei City, Taiwan
🇨🇳China Medical University Hospital, Taichung, Taiwan
🇨🇳Taichung Veterans General Hospital, Taichung, Taiwan
A Study of DS-8201a in Metastatic Breast Cancer Previously Treated With Trastuzumab Emtansine (T-DM1)
- First Posted Date
- 2017-08-14
- Last Posted Date
- 2025-06-26
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 253
- Registration Number
- NCT03248492
- Locations
- 🇺🇸
Alaska Urological Institute dba Alaska Clinical Research Center, Anchorage, Alaska, United States
🇺🇸Arizona Oncology Associates, Tucson, Arizona, United States
🇺🇸The Regents of the University of California, Los Angeles, California, United States
Effect of Probenecid on Pexidartinib Pharmacokinetics
- Conditions
- Pharmacokinetics in Healthy Volunteers
- Interventions
- First Posted Date
- 2017-05-03
- Last Posted Date
- 2017-05-03
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 16
- Registration Number
- NCT03138759
- Locations
- 🇺🇸
Worldwide Clinical Trials Early Phase Services, San Antonio, Texas, United States
DS-3201b for Acute Myelogenous Leukemia (AML) or Acute Lymphocytic Leukemia (ALL)
- Conditions
- Leukemia, Myeloid, AcuteLeukemia, Lymphocytic, Acute
- Interventions
- First Posted Date
- 2017-04-12
- Last Posted Date
- 2024-01-31
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 28
- Registration Number
- NCT03110354
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸University of Michigan, Ann Arbor, Michigan, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
Study of DS-1001b in Patients With Gene IDH1-Mutated Gliomas
- First Posted Date
- 2017-01-24
- Last Posted Date
- 2025-03-20
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 47
- Registration Number
- NCT03030066
- Locations
- 🇯🇵
National Cancer Center Hospital, Tokyo, Japan
Antibody DS-8273a Administered in Combination With Nivolumab in Subjects With Advanced Colorectal Cancer
- First Posted Date
- 2016-12-13
- Last Posted Date
- 2019-02-12
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 4
- Registration Number
- NCT02991196
- Locations
- 🇺🇸
Georgetown University Medical Center, Washington, District of Columbia, United States
🇺🇸South Texas Accelerated Research Therapeutics (START) Midwest, Grand Rapids, Michigan, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
Comparison of Two Doses of Edoxaban Using Different Tests (Assays) and Clinical Outcomes
- First Posted Date
- 2016-11-16
- Last Posted Date
- 2019-02-12
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 607
- Registration Number
- NCT02964949
- Locations
- 🇧🇪
O L V Ziekenhuis, Aalst, Belgium
🇧🇪ZNA Middelheim, Antwerpen, Belgium
🇧🇪AZ Sint-Jan Brugge, Brugge, Belgium
Edoxaban Treatment in Routine Clinical Practice in Patients With Venous Thromboembolism in Korea and Taiwan (ETNA-VTE-KOR-TWN)
- First Posted Date
- 2016-11-02
- Last Posted Date
- 2019-12-23
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 352
- Registration Number
- NCT02952599
- Locations
- 🇰🇷
SoonChunHyang University Hospital Gumi, Gyeongsang, Gumi, Korea, Republic of
🇰🇷Inje University Haeundae Paik Hospital, Busan, Haeundae-gu, Korea, Republic of
🇰🇷Seoul National University Hospital, Seoul, Jongno-gu, Korea, Republic of
Edoxaban Treatment in Routine Clinical Practice for Patients With Atrial Fibrillation in Korea and Taiwan (ETNA-AF-KOR-TWN)
- First Posted Date
- 2016-11-01
- Last Posted Date
- 2021-01-12
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 3008
- Registration Number
- NCT02951039
- Locations
- 🇰🇷
Soon Chun Hyang University Hospital Cheonan, Cheonan, Chungcheongnam-do, Korea, Republic of
🇰🇷GangNeung Asan Hospital, Gangneung, Gangwon-do, Korea, Republic of
🇰🇷Yonsei University, Wonju Severance Christian Hospital, Wŏnju, Gangwon-do, Korea, Republic of